P3 Health Partners (PIII)
(Delayed Data from NSDQ)
$0.62 USD
+0.01 (1.70%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $0.63 +0.01 (1.55%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PIII 0.62 +0.01(1.70%)
Will PIII be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PIII based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PIII
P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
3 Medical Info Systems Stocks to Buy as Industry Rebounds
PIII: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights P3 Health Partners, Talkspace and Augmedix
3 Medical Info Systems Stocks to Buy as Industry Trends Improve
Here's Why P3 Health Partners Inc. (PIII) is Poised for a Turnaround After Losing -28.57% in 4 Weeks
Other News for PIII
P3 Health Partners Schedules Second Quarter 2024 Earnings Release and Conference Call
P3 Health Partners Forms Strategic Partnership with Innovaccer to Drive Value-Based Care and Patient Experience
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
P3 Health Partners files to sell 134.77M shares of Class A common for holders
P3 Health Partners: Moving In The Right Direction In 2024